Abcam Launches Unique Range of Epitomics’ RabMAbs®

Abcam plc is delighted to announce that following the acquisition of Epitomics, Inc. in April this year, it has launched a unique range of Rabbit Monoclonal antibodies (RabMAbs).

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

(PRWEB UK) 7 September 2012

Abcam plc is delighted to announce that following the acquisition of Epitomics, Inc. in April this year, it has launched a unique range of Rabbit Monoclonal antibodies (RabMAbs).

RabMAbs provide the combined benefits of superior antigen recognition of the rabbit immune system with the specificity and consistency of a monoclonal antibody, bringing you the highest quality antibody possible.

The integration of Epitomics’ line of high quality RabMAbs on to Abcam’s extensive catalogue now enables most European customers to receive next day delivery.

The addition of Epitomics’ unique RabMAbs to Abcam’s product portfolio, combined with Abcam’s powerful e-Commerce capability, helps Abcam achieve its vision of becoming the world’s leading supplier of life science research tools.

The product range is now integrated into Abcam’s website and is available through authorized distributors.

Commenting on the announcement, Jonathan Milner, Chief Executive Officer, Abcam plc, said:

“We live in a golden age of biology where, almost daily, enormous breakthroughs are being made in mankind’s understanding of how cells operate in health and disease. These breakthroughs are possible owing to the rapid growth in understanding at a molecular level of the role of proteins within the cellular environment.

Abcam’s mission is to help scientists and medical researchers in their quest to unravel the huge complexity of protein function by offering the biggest range of the best life science research tools in the world. Epitomics’ best-in-class RabMAbs are superb products that will help propel Abcam towards achieving its mission of enabling the research community to discover more.”

Guo-Liang Yu, CEO and President of Epitomics - an Abcam Company added:

“We are very pleased to have successfully completed the acquisition and excited to be joining Abcam, a leading provider of life science research tools. This acquisition will allow us to continue to develop our line of high quality rabbit monoclonal antibodies and introduce even more researchers to our technology, products and services. It has always been our goal to help advance research by providing best-in-class antibodies and this acquisition only helps to enhance this.”

About Epitomics
Epitomics, Inc. is a biotechnology company dedicated to developing breakthrough rabbit monoclonal antibody technology for research and diagnostic applications. The Company's core technology is its unique and proprietary RabMAb® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays.

Epitomics, Inc. was founded in 2001, headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.

Epitomics, Inc. is now known as Epitomics - an Abcam Company.

For further information contact:
Abcam: +44 (0) 1223 696000
Epitomics: (877) 772-2622 (Toll Free North America)
(650) 583-6688


Contact

  • Francesca Axe
    Abcam
    +44 (0)1223 696000
    Email